On Oct. 20, E. Donnall Thomas, the “father of bone marrow transplantation,” died at age 92.
News & Commentaries
On July 26, the California Institute of Regenerative Medicine announced $151 million worth of grants for research that would take stem cell therapies from the laboratory to the clinic.
Two years ago, Pamela Robey broke two bones in her leg, a consequence of snow outside and an errant boot. “I slipped and my boot heel got caught in a crack,” she says. “I was moving very fast but my leg was not.”
If there is a scientific analog of having one’s cake and eating it too, it would have to be iPS cells.
The stem cell community recorded something of a milestone this past month.
In the Oct. 20 issue of Nature, researchers at the Wellcome Trust Sanger Institute and Sangamo BioSciences, reported some dramatic results in the field of stem cell therapeutics. 
The fast-paced, vibrant world of stem cell science has more than its fair share of brilliant minds. Many probably have at one time or another considered striking out on their own to market some new invention from their lab.
Human development is the work of stem cells.
On April 19, Geron Corp. presented safety data on the first patient in its groundbreaking clinical trial of GRNOPC1.
On January 3, stem cell therapeutics company Advanced Cell Technology (ACT) announced it had received approval from the US Food and Drug Administration to kick off a Phase I/II clinical trial using the company's retinal epithelial cells (RPE).